Free Trial
NASDAQ:IMVT

Immunovant (IMVT) Stock Price, News & Analysis

Immunovant logo
$18.23 +0.29 (+1.59%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immunovant Stock (NASDAQ:IMVT)

Key Stats

Today's Range
$18.02
$18.89
50-Day Range
$13.78
$18.59
52-Week Range
$12.72
$34.47
Volume
926,960 shs
Average Volume
1.48 million shs
Market Capitalization
$3.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.30
Consensus Rating
Moderate Buy

Company Overview

Immunovant Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

IMVT MarketRank™: 

Immunovant scored higher than 31% of companies evaluated by MarketBeat, and ranked 756th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunovant has only been the subject of 1 research reports in the past 90 days.

  • Read more about Immunovant's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunovant are expected to decrease in the coming year, from ($2.69) to ($3.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunovant is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunovant is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunovant has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunovant's valuation and earnings.
  • Percentage of Shares Shorted

    29.79% of the float of Immunovant has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunovant has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunovant has recently increased by 2.61%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Immunovant does not currently pay a dividend.

  • Dividend Growth

    Immunovant does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    29.79% of the float of Immunovant has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunovant has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunovant has recently increased by 2.61%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Immunovant has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
  • Search Interest

    Only 3 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Immunovant to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $109,398.00 in company stock.

  • Percentage Held by Insiders

    Only 1.80% of the stock of Immunovant is held by insiders.

  • Percentage Held by Institutions

    47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunovant's insider trading history.
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Stock News Headlines

Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.
Immunovant, Inc. (IMVT) - Yahoo Finance
Tracking Baker Brothers Portfolio - Q1 2025 Update
See More Headlines

IMVT Stock Analysis - Frequently Asked Questions

Immunovant's stock was trading at $24.77 at the beginning of 2025. Since then, IMVT shares have decreased by 26.3% and is now trading at $18.2620.

Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings results on Thursday, May, 29th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.08. The business earned $0.16 million during the quarter.

Top institutional shareholders of Immunovant include Platinum Investment Management Ltd. (0.11%), Banque Pictet & Cie SA (0.07%), KLP Kapitalforvaltning AS (0.01%) and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, Frank Torti, William L Macias, Mark S Levine, Michael Geffner, Jay S Stout and Andrew J Fromkin.
View institutional ownership trends
.

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/29/2025
Today
7/23/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMVT
CIK
1764013
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$53.00
Low Price Target
$17.00
Potential Upside/Downside
+95.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$413.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-80.60%
Return on Assets
-71.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.16
Quick Ratio
11.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.16 per share
Price / Book
4.47

Miscellaneous

Outstanding Shares
171,069,000
Free Float
167,990,000
Market Cap
$3.18 billion
Optionable
Optionable
Beta
0.63
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IMVT) was last updated on 7/23/2025 by MarketBeat.com Staff
From Our Partners